Marija Balic, Co-director of Magee Womens Cancer Program at University of Pittsburgh School of Medicine, shared a post on Linkedln about a recent article she and her colleagues co-authored, adding:
“Following the publication of one of the early neoadjuvant studies demonstrating the association between lack of cDNA clearance and higher residual cancer burden (RCB), we showed that cDNA can serve as a valuable tool for monitoring treatment response and potentially guiding therapeutic adaptation.
Generating robust long-term follow-up data beyond the primary clinical trial endpoints, however, requires substantial collaborative effort.
ABCSG recognized early the importance of systematic biomarker collection and an academically driven approach to translational research. We are pleased to share our recently published long-term outcome analyses.”
Title: Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial
Authors: Daniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christian Singer, Georg Pfeiler, Rupert Bartsch, Gregor Huber, Angelika Pichler, Edgar Petru, Zsuzsanna Bago-Horvath, Anna-Sophia Kermanidis, Christian Fesl, Qing Zhou, Ricarda Graf, Sabrina Hammer, Nadia Dandachi, Martin Filipits, Michael Gnant, Ellen Heitzer, Marija Balic
Read the Full Article on npj Breast Cancer
Other articles about breast cancer on OncoDaily.